Trends in incidence and mortality of esophageal cancer in Inner Mongolia, 2010-2015.

Abstract:

BACKGROUND:Esophageal cancer is among the leading cancer types in Inner Mongolia. This study aimed to investigate the incidence and mortality rates of esophageal cancer in 2015 and the trends in these rates in the 2010-2015 period in this region. METHODS:National Colorectal Cancer Roundtable (NCCR) screening methods and criteria were used to extract data from 10 cancer registries stratified by area (urban/rural), sex, and age group. The Chinese standard population in 2000 and Segi's world population were used to calculate age-standardized rates. The annual percentage change (APC) in these rates was calculated using the Joinpoint Regression Program. RESULTS:In 2015, Inner Mongolia had 4324 new cases (4027 male vs. 297 female patients) and 3559 deaths (3300 male vs. 259 female patients) from esophageal cancer. The crude incidence, age-standardized incidence by Chinese population, age-standardized incidence by world population, and cumulative incidence were 13.45/100 000, 9.92/100 000, 10.18/100 000, and 1.30%, respectively. The corresponding figures for mortality were 11.32/100 000, 8.35/100 000, 8.53/100 000, and 1.04%. The incidence and mortality increased with age between 40 and 80 years. The rates in rural dwellers, especially men, showed negative APC (-13.25% vs. -11.08%; P < 0.05). CONCLUSIONS:The incidence and mortality rates of esophageal cancer in Inner Mongolia increased between 2010 and 2015. The rates were higher in men in rural areas, middle-aged and elderly individuals. Prevention and control programs focused on these groups, in addition to early diagnosis and treatment of esophageal cancer, are needed to reduce these rates. KEY POINTS:Significant findings of the study: In Inner Mongolia, incidence and mortality rates of esophageal cancer were higher in urban areas than in rural areas and in men than in women between 2010 and 2015, and in middle-aged and elderly than in younger people. WHAT THIS STUDY ADDS:Prevention and control programs, in addition to early diagnosis and treatment of esophageal cancer, should be tailored to specifically target men in rural areas and middle-aged and elderly individuals in order to reduce the incidence and mortality rates of this pathology.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Xi Y,Dong W,Qiao L,Han K,Chen W,Wang W

doi

10.1111/1759-7714.13552

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

2440-2448

issue

9

eissn

1759-7706

issn

1759-7714

journal_volume

11

pub_type

杂志文章
  • Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

    abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12275

    authors: Sun H,Sun X,Zhai X,Guo J,Liu Y,Ying J,Wang Z

    更新日期:2016-01-01 00:00:00

  • Esophagogastric reconstruction using remnant stomach with a single vessel pedicel: Technique and outcomes.

    abstract::Esophageal cancer with a history of distal gastrectomy is a clinical problem. To our knowledge there have been no reports of remnant stomach fed from the left gastroepiploic artery being used in esophageal reconstruction. We, herein, report four cases of esophagogastric reconstruction using remnant stomach with a sing...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12054

    authors: You B,Hou SC,Li H,Hu B

    更新日期:2014-03-01 00:00:00

  • Use of glucocorticoids in the management of immunotherapy-related adverse effects.

    abstract::Immune checkpoint inhibitors (ICIs) activate host antitumor immunity to kill tumor cells. However, ICI therapy may be accompanied by a series of immunotherapy-related adverse effects (irAEs) caused by activated autoreactive T cells. Glucocorticoids are the mainstream therapy for irAEs. However, the usage, dosage and c...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13589

    authors: Wang H,Zhou J,Guo X,Li Y,Duan L,Si X,Zhang L

    更新日期:2020-10-01 00:00:00

  • Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.

    abstract:BACKGROUND:Most non-small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK-TKI therapies; however, little clinical data exists on the clinical ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13143

    authors: Haratake N,Seto T,Takamori S,Toyozawa R,Nosaki K,Miura N,Ohba T,Toyokawa G,Taguchi K,Yamaguchi M,Shimokawa M,Takenoyama M

    更新日期:2019-09-01 00:00:00

  • Basic fibroblast growth factor shows prognostic impact on survival in operable non-small cell lung cancer patients.

    abstract:BACKGROUND:The important role of angiogenesis displaying in tumor development and metastasis has been generally realized. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and endostatin (ES) are critical members of angiogenesis modulating the balance between pro-angiogenenic and anti-ang...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12202

    authors: Hu MM,Hu Y,Gao GK,Han Y,Shi GL,Li BL

    更新日期:2015-07-01 00:00:00

  • Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm.

    abstract:BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13336

    authors: Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS

    更新日期:2020-04-01 00:00:00

  • Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients.

    abstract:BACKGROUND:A single institution retrospective analysis of 124 non-small cell lung carcinoma (NSCLC) patients was performed to identify whether disease-free survival (DFS) achieves incremental values when radiomic and genomic data are combined with clinical information. METHODS:Using the least absolute shrinkage and se...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13568

    authors: Kim KH,Kim J,Park H,Kim H,Lee SH,Sohn I,Lee HY,Park WY

    更新日期:2020-09-01 00:00:00

  • Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

    abstract:BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12762

    authors: Kim TO,Oh IJ,Kho BG,Park HY,Chang JS,Park CK,Shin HJ,Lim JH,Kwon YS,Kim YI,Lim SC,Kim YC,Choi YD

    更新日期:2018-07-01 00:00:00

  • Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib.

    abstract::Tyrosine kinase inhibitors are used as first-line treatment for non-small cell lung cancer (NSCLC) patients harboring driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, standard molecular testing approaches help identify single genes for such targetable driver mutations in NSCLC; however, next-generation sequen...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13694

    authors: Onozawa H,Saito H,Sunami K,Kubo T,Yamamoto N,Kasajima R,Ohtsu T,Hiroshima Y,Kanamori H,Yokose T,Miyagi Y

    更新日期:2020-12-01 00:00:00

  • Circulating tumor cells in the pulmonary vein increase significantly after lobectomy: A prospective observational study.

    abstract:BACKGROUND:It has been reported that there are more circulating tumor cells (CTCs) in the pulmonary vein (PV) than in the peripheral blood; however, it is unclear whether the CTC count changes in the PV after resection of a lung lobe. METHODS:Thirty-three lung cancer patients were recruited for the study, including 17...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12925

    authors: Duan X,Zhu Y,Cui Y,Yang Z,Zhou S,Han Y,Yu D,Xiao N,Cao X,Li Y,Liu S,Wang Z,Zhang W,Feng L,Zhang K,Shou J,Liu Z,Xu S

    更新日期:2019-02-01 00:00:00

  • Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation.

    abstract:BACKGROUND:Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are compared. METHODS:One...

    journal_title:Thoracic cancer

    pub_type: 临床试验,杂志文章

    doi:10.1111/1759-7714.12966

    authors: Zehentmayr F,Sprenger M,Rettenbacher L,Wass R,Porsch P,Fastner G,Pirich C,Studnicka M,Sedlmayer F

    更新日期:2019-02-01 00:00:00

  • Osimertinib-induced severe interstitial lung disease: A case report.

    abstract::Lung cancer is globally one of the leading causes of malignant tumor-related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78-year-old ma...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13127

    authors: Fan M,Mo T,Shen L,Yang L

    更新日期:2019-07-01 00:00:00

  • SUMO1 promotes the proliferation and invasion of non-small cell lung cancer cells by regulating NF-κB.

    abstract:BACKGROUND:Our previous study showed that SUMO1 expression is closely related to progression in non-small cell lung cancer (NSCLC); however, the function of SUMO1 in NSCLC has not yet been well elucidated. METHODS:SUMO1 was enhanced or silenced in two NSCLC cell lines by using either forced SUMO1 expression or short h...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12895

    authors: Ke C,Zhu K,Sun Y,Ni Y,Zhang Z,Li X

    更新日期:2019-01-01 00:00:00

  • FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas.

    abstract:BACKGROUND:Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 amplification as a potential therapeutic target for LSCC are not well understood....

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12504

    authors: Zhang X,Kong M,Zhang Z,Xu S,Yan F,Wei L,Zhou J

    更新日期:2017-11-01 00:00:00

  • Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival.

    abstract:BACKGROUND:The prognostic effect of molecular subtypes on male breast cancer (MBC) remains unclear. The aim of this study was to evaluate the clinicopathological and prognostic factors of MBC patients. METHODS:From 1 January 1990 to 31 December 2014, the data of 152 MBC and 304 female breast cancer (FBC) patients were...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13611

    authors: Zhao J,Wang B,Zhao J,Mao Y,Liu J,Yang Y

    更新日期:2020-11-01 00:00:00

  • LncRNA SNHG1 influences cell proliferation, migration, invasion, and apoptosis of non-small cell lung cancer cells via the miR-361-3p/FRAT1 axis.

    abstract:BACKGROUND:Non-small-cell lung cancer (NSCLC) is the most lethal type of cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified as crucial regulators in the development of NSCLC. The aim of our study was to explore the molecular mechanism of SNHG1 to enable better treatment for NSCLC patient...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13256

    authors: Li X,Zheng H

    更新日期:2020-02-01 00:00:00

  • Hsa_circRNA_0000518 facilitates breast cancer development via regulation of the miR-326/FGFR1 axis.

    abstract:BACKGROUND:Breast cancer (BC) is a heterogeneous malignant tumor that threatens the health of women worldwide. Hsa_circRNA_0000518 (circ_0000518) has been revealed to be upregulated in BC tissues. However, the role and mechanism of circ_0000518 in BC are indistinct. METHODS:Quantitative real-time polymerase chain reac...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13641

    authors: Jiang J,Lin H,Shi S,Hong Y,Bai X,Cao X

    更新日期:2020-11-01 00:00:00

  • Expression of Pax8 is decreased and bortezomib does not increase the iodine uptake in thyroid carcinoma cells.

    abstract::Fundamental treatment for papillary thyroid carcinoma (PTC) involves total or subtotal thyroidectomy. Iodine-131 ((131)I) is routinely utilized to target remnant thyroid cancer and metastasis after thyroidectomy. The effectiveness of other therapeutic modalities remains unsatisfactory; thus, these patients have a poor...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12277

    authors: Wang HJ,Yao JM,Zhang ZW,Zhao JY,Shang HX,Liao L,Dong JJ

    更新日期:2015-11-01 00:00:00

  • Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review.

    abstract::Here, we report two cases of advanced non-small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma, cT1cN3M1c, stage IV...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13600

    authors: Shan Q,Wang H,Han X,Guo J,Wang Z

    更新日期:2020-10-01 00:00:00

  • A nurse-driven enhanced recovery after surgery (ERAS) nursing program for geriatric patients following lung surgery.

    abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13372

    authors: Li Y,Yan C,Li J,Wang Q,Zhang J,Qiang W,Qi D

    更新日期:2020-04-01 00:00:00

  • Video-assisted thoracoscopy in the management of intrapleural extravasation of cytotoxic chemotherapy.

    abstract::The extravasation of cytotoxic agents into subcutaneous tissue is a serious complication of chemotherapy. Unfortunately, if such extravasation occurs into the pleural space, limited data is available to guide appropriate management. We present the first report in the literature of video-assisted thoracoscopy combined ...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12430

    authors: Aguirre VJ,Barnett D,Burdett N,Joshi R,Viana FF

    更新日期:2017-07-01 00:00:00

  • Surgical results of resectable small cell lung cancer.

    abstract:BACKGROUND:The standard of care for patients with small cell lung cancer (SCLC) is chemotherapy and radiotherapy, even for patients with limited disease. To define the role of surgical resection in patients with limited SCLC, we investigated the outcomes of patients diagnosed with limited-stage disease (LD) SCLC. METH...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12154

    authors: Kawano D,Okamoto T,Fujishita T,Suzuki Y,Kitahara H,Shimamatsu S,Maehara Y

    更新日期:2015-03-01 00:00:00

  • Epidemiology of lung cancer in China.

    abstract:BACKGROUND:Lung cancer is the most common cancer and the leading cause of cancer death in China. Along with socioeconomic development, environmental problems have intensified and the burden of lung cancer continues to increase. METHODS:In this study, national cancer registry data was used for evaluating incidence, mor...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12169

    authors: Chen W,Zheng R,Zeng H,Zhang S

    更新日期:2015-03-01 00:00:00

  • Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO).

    abstract:BACKGROUND:Soft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outc...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12150

    authors: Unal OU,Oztop I,Yasar N,Urakci Z,Ozatli T,Bozkurt O,Sevinc A,Gunaydin Y,Yapar Taskoylu B,Arpaci E,Ulas A,Kodaz H,Tonyali O,Avci N,Aksoy A,Yilmaz AU

    更新日期:2015-01-01 00:00:00

  • Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.

    abstract:BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13526

    authors: Kasahara N,Imai H,Naruse I,Tsukagoshi Y,Kotake M,Sunaga N,Kaira K,Maeno T,Asao T,Hisada T

    更新日期:2020-08-01 00:00:00

  • A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.

    abstract:BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two gro...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13238

    authors: Nie K,Zhang Z,You Y,Zhuang X,Zhang C,Ji Y

    更新日期:2020-01-01 00:00:00

  • Lung cancer surgery in HIV-infected patients: An analysis of postoperative complications and long-term survival.

    abstract:BACKGROUND:The purpose of this study was to investigate the risk factors of postoperative complications and reliable prognostic factors of long-term survival in HIV-infected patients with non-small cell lung cancer (NSCLC). METHODS:HIV-infected patients with NSCLC who underwent surgical treatment were retrospectively ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13519

    authors: Wang L,Chen Y,Wang Y,Liu J,Wen Z,Chen H,Zhu Y,Wang J,Wan L,Li F,Song Y

    更新日期:2020-08-01 00:00:00

  • Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients.

    abstract:BACKGROUND:Achaete-scute homolog 1 (ASCL1) is a basic helix-loop-helix transcription factor and is essential in the differentiation of neuroendocrine cells and neural tissues. ASCL1 is frequently overexpressed in small cell lung cancer (SCLC) and plays a crucial role in the pathogenesis of SCLC. METHODS:This study was...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13212

    authors: Kim JH,Lee SY,Choi JE,Do SK,Lee JH,Hong MJ,Kang HG,Lee WK,Shin KM,Jeong JY,Choi SH,Lee YH,Seo H,Yoo SS,Lee J,Cha SI,Kim CH,Park JY

    更新日期:2020-01-01 00:00:00

  • Air bronchogram in pleomorphic carcinoma of the lung is associated with favorable prognosis.

    abstract:BACKGROUND:Pleomorphic carcinoma (PC) of the lung is a rare histological type of lung carcinoma. The association between computed tomography (CT) findings and histology with outcome remains unclear. We examined the relationships between CT features and histopathologic findings, and evaluated the impact of CT features a...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12638

    authors: Onoda H,Kimura T,Tao H,Okabe K,Matsumoto T,Ikeda E

    更新日期:2018-06-01 00:00:00

  • Cloning short DNA into plasmids by one-step PCR.

    abstract:BACKGROUND:Plasmid construction of small fragments of interest (such as insertion of small fragment marker genes, expression of shRNA, siRNA, etc) is the basis of many biomolecular experiments. Here, we describe a method to clone short DNA into vectors by polymerase chain reaction (PCR), named one-step PCR cloning. Our...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13660

    authors: Tao CC,Yang Y,Li F,Qiao L,Wu Y,Sun XD,Zhang YY,Li CL

    更新日期:2020-11-01 00:00:00